Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIMIT: Binimetinib and Hydroxychloroquine in KRAS-Mutant NSCLC
NCT04735068Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Apr 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of binimetinib, hydroxychloroquine in non-small cell lung cancer (NSCLC), sponsored by Abramson Cancer Center. Started Apr 2021; status: completed.
02
Drugs
binimetinibhydroxychloroquine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04735068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04735068.